welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
study id #: NCT01483144
condition: Familial Adenomatous Polyposis
status: completed
purpose:The purpose of this randomized, double-blind, Phase III trial is to determine if the combination of eflornithine plus sulindac is superior to sulindac or eflornithine as single agents in delaying time to the first occurrence of any FAP-related event. This includes:
1) FAP related disease progression indicating the need for excisional intervention involving the colon, rectum, pouch, duodenum and/or
2) clinically important events which includes progression to more advanced duodenal polyposis, cancer or death.
intervention:
Drug: Eflornithine plus Sulindac
Drug: Eflornithine and Placebo
Drug: Sulindac and Placebo
expertly curated content related to this topic
-
Anorectal Functional Outcome After Repeated Transanal Endoscopic MicrosurgeryAIM : To evaluate the status of anorecta...
-
Tucson drug startup launches gastric-cancer trialTucson-based drug startup Cancer...
-
Familial Investigations of Childhood Cancer PredispositionWhile it is well recognized that heredit...
-
Bonnies Diary Nov 07https://jtvcancersupport.com/embed/26653...
-
Proctocolectomy for Ulcerative Colitis or Familial Adenomatous Polyposishttps://www.youtube.com/watch?v=zlxBwxKX...
-
Laparoscopic Restorative Proctocolectomy: Case-Matched Comparative Study with Open Restorative ProctocolectomyPURPOSE : A laparoscopic approach to res...
-
Ureteric Obstruction in Familial Adenomatous Polyposis-Associated Desmoid DiseasePURPOSE : Intra-abdominal desmoid diseas...